Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis.

Tobias ZrzavyEsther DanielsNiklas StukaDennis WeberAlexander WinkelmannHelmut RauschkaMichael HeckerFahmy Aboulenein-DjamshidianStefanie MeisterFritz LeutmezerThomas BergerGabriel BstehUwe Klaus ZettlPaulus Rommer

Published in: Therapeutic advances in chronic disease (2021)

RTX shows comparable effectiveness but a favorable safety profile compared with MTX in active RMS.

Keyphrases

multiple sclerosis
randomized controlled trial
diffuse large b cell lymphoma
white matter
systematic review
chronic lymphocytic leukemia
hodgkin lymphoma